View Older Stories View More Recent Stories
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put into quarter results
-
Eli Lilly plans $3.5 billion Pennsylvania manufacturing facility
-
Eli Lilly extends claims data collection to all 340B pharmacy purchases
-
Seamless Therapeutics partners with Eli Lilly on hearing loss gene therapy
-
Walmart raises pharmacy technician wages as it expands healthcare services
-
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
Bernstein on Eli Lilly (LLY): 'Our Top Pick With $1300 PT'
-
Lilly receives FDA breakthrough therapy designation for ovarian cancer drug
-
Eli Lilly (LLY) PT Lowered to $1,161 at Guggenheim
-
Morgan Stanle on Eli Lilly (LLY): 'We see three potential scenarios for REDEFINE4'
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put with a focus as share price up 1.5%
-
Novo Nordisk's oral Wegovy reaches 3,071 prescriptions in first four days
-
FDA delays reviews of Sanofi's Tzield and Disc Medicine's bitopertin
-
BMO Capital on Eli Lilly (LLY): 'We See Strengthening Leadership in Obesity and Beyond in 2026+'
-
Novo Nordisk CEO warns of international competition headwinds, cites Lilly
-
Novo Nordisk (NVO) EVP for product and portfolio strategy: market for oral weight-loss drugs versus injectables bigger than originally thought
-
NVIDIA and Lilly launch $1 billion AI lab for drug discovery
-
NVIDIA partners with Lilly for $1 billion AI drug discovery lab
-
Abivax shares trim gains after French Finance Ministry statement
-
Abivax shares surge after report flags continued Eli Lilly takeover interest
-
Schrodinger Inc. (SDGR) Partners with Lilly to Make TuneLab Platform Available in LiveDesign
-
Lilly's combined Taltz and Zepbound therapy shows promise in psoriatic arthritis
-
Eli Lilly & Co. (LLY) calls more active than puts into the annual J.P. Morgan Healthcare Conference
-
Bernstein: 'This Is a Good Deal for Eli Lilly (LLY)'
-
Eli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald
-
Lilly to acquire Ventyx Biosciences for $1.2 billion in cash
-
UBS Assumes Eli Lilly (LLY) at Buy
-
After-hours movers: Strategy, Mobileye, Ventyx Bioscience, Praxis
-
Ventyx Biosciences (VTYX) halted on volatility following WSJ report
-
Eli Lilly & Co. (LLY) Nears Deal for Ventyx Biosciences (VTYX) - WSJ
-
Analysts expect this mega-cap pharma stock to outperform this year
-
Eli Lilly (LLY) PT Raised to $1,234 at Leerink Partners
-
Goldman Sachs: 'top themes we're tracking for 2026'
-
Abivax soars on report of Eli Lilly meeting French officials over possible deal
-
Here's the list of top biotech stocks to own for 2026
-
Trump to announce prescription drug price agreements
-
Bernstein on Eli Lilly (LLY): Orforglipron De-Risks the Oral GLP-1 Path
-
RBC: 'We have just confirmed that a recent clinicaltrials.gov listing for a new drug called BIIB145'
-
Leerink on Eli Lilly (LLY): 'Orforglipron Delivers Weight Maintenance Following Injectables'
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Goldman Sachs Reiterates Buy Rating on Eli Lilly (LLY)
-
BofA Comments on GLP-1s and Potential Pressure Ahead
-
Daiwa Securities Upgrades Eli Lilly (LLY) to Buy (1)
-
Lilly reports updated breast cancer drug data at medical conference
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY) Following Topline Results
-
BMO Capital on Eli Lilly (LLY): 'A True TRIUMPH'
-
FDA reportedly pressing for reviewers to speed up evaluation of Eli Lilly's weight-loss pill
